Background: Pretransplant functional imaging (FI), particularly a negative positron emission tomography (PET), is a strong predictor of outcome in adults with relapsed or refractory Hodgkin lymphoma (HL), but data in pediatrics are limited.
INTRODUCTION
Children and adolescents with Hodgkin lymphoma (HL) have excellent long-term survival exceeding 95% after combined modality treatment. 1 However depending on disease stage, about 5-15%
Abbreviations: ASCT, autologous stem cell transplant; CI, confidence interval; CT, computer tomography; FDG-PET, 18-fluoro-2-deoxy-D-glucose positron emission tomography; FI, functional imaging; HL, Hodgkin lymphoma; ICE, ifosfamide, carboplatin, and etoposide; IFRT, involved field radiation therapy; OS, overall survival; PFS, progression-free survival; RT, radiotherapy will either relapse after initial therapy or have primary refractory disease. [2] [3] [4] [5] Many of these patients cannot be salvaged with chemotherapy and/or radiotherapy (RT) alone, hence salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant (ASCT) has become the standard of care for majority of pediatric patients with relapsed or refractory HL. 6 In adults, achieving a complete remission by functional imaging (FI), particularly a negative 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) after salvage chemotherapy is a strong predictor of outcome after ASCT. 7 a systematic review examining the prognostic value of FDG-PET in patients with relapsed/refractory HL who received ASCT. The authors concluded there was only moderate quality evidence to suggest that pretransplant PET was predictive of outcome, given a considerable proportion of PET positive patients in the studies analyzed remained disease free and some PET negative patients had relapsed post-ASCT. 9 The majority of published literatures in pediatric cohorts have employed computed tomography (CT) measurements to assess pretransplant disease status, [10] [11] [12] and data on the predictive value of pretransplant FI in pediatrics are very limited. Based on the adult experience, the treatment approach at the Dana Farber/Boston Children's Cancer and Blood Disorders Center (DF/BC CBDC) has focused on getting patients with relapsed or refractory HL into complete metabolic remission before autologous transplant. This often involves administering additional lines of salvage chemotherapy to patients who failed to achieve metabolic remission after first-line salvage chemotherapy. We report our experience and the outcome of fortynine consecutive children and adolescents, who underwent ASCT for relapsed or refractory HL at our institution.
PATIENTS AND METHODS
This retrospective study was reviewed and approved by the Institu- Twenty-two out of 49 patients in this analysis received salvage chemotherapy at other institutions and were referred to DF/BC CBDC for ASCT. The choices of salvage chemotherapy regimens were at the treating physician's discretion. All patients received standard conditioning regimen with carmustine, etoposide, cytarabine, melphalan (BEAM) as follows: carmustine (BCNU) 300 mg/m 2 on day -6; etoposide 200 mg/m 2 every 12 hr on days -5, -4, -3, cytarabine 100 mg/m 2 every 12 hr on days -5, -4, -3, -2; and melphalan 140 mg/m 2 on day -1. This was followed by stem cell infusion on day 0. Granulocyte colony stimulation factor was begun on day +5 until absolute neutrophil count > 2,000 cells/ l for two consecutive days. Posttransplant involvedfield radiotherapy (IFRT) was given if no prior RT had been administered to the site(s) of relapse or if there was persistent gallium or FDGavid disease pretransplant.
Pretransplant metabolic status
All patients had CT, and either FDG-PET or gallium at the time of relapse, after each line of salvage chemotherapy and prior to ASCT.
All 49 patients had a positive FI at the time of relapse, and in all cases imaging was obtained within 2-4 weeks of admission for ASCT to document final pretransplant disease status. Six patients transplanted before December 2004, had gallium scans, and 43 subsequent patients had FDG-PET (Fig. 1) .
The study period began prior to the publication of the five-point Deauville criteria, 13 
Definitions of refractory disease or relapse
Refractory disease was defined as no response to primary treatment or progression (increase in size of known lesions and/or a new disease site) on or within 3 months of completion of planned treatment.
A relapse occurring 3-12 months after completion of therapy was defined as an early relapse, and any relapse >12 months postcompletion of initial therapy was called a late relapse. The time to relapse was calculated from the date of completion of upfront treatment to the documented date of relapse.
Statistical analysis
Overall survival (OS) was calculated from the date of stem cell infusion to death from any cause. Progression-free survival (PFS) was calculated from date of stem cell infusion to relapse of HL or death from any cause. Survival distributions were examined using Kaplan-Meier curves and the differences between groups analyzed using the log-rank test and a significant P value < 0⋅05. All statistical analyses were performed using Stata version 14.1 (StataCorp, College Station, TX).
RESULTS

Patient characteristics
Patient characteristics are detailed in Table 1 
Response to salvage chemotherapy
Front-line and salvage therapy regimens are shown in Table 2 . The most common first-line salvage regimen used was ifosfamide, carboplatin, and etoposide (ICE), which was administered to 55% of patients. Gemcitabine/vinorelbine was the most common second-line salvage regimen. The median number of salvage chemotherapy cycles administered pre-ASCT was two cycles (range two to eight cycles).
Thirty-two patients (65%) were in complete remission by either PET or gallium after two cycles of first-line salvage therapy (Fig. 2) .
Of the 17 patients who did not respond adequately, nine patients had primary refractory disease, six of them were early relapses, and two patients had a late relapse. Three of these 17 patients proceeded to ASCT without further salvage therapy, whereas the remaining 14 patients received additional second-line salvage therapy. As shown 
Survival and outcome analysis
Forty-five patients were alive and disease free at the median follow (Fig. 3B) .
In a univariate analysis, known prognostic factors, including remission status less than 12 months, refractory disease, extranodal disease at relapse, B symptoms at relapse, in radiation field relapse, or failure to respond to first-line salvage chemotherapy, did not have any significant impact on PFS or OS (Supplementary Table S1 ). This was not unexpected given the rarity of events. Also, Cox proportional hazard ratios could not be performed on multivariate analysis for the same reasons.
Treatment-related toxicity and deaths
There were three nonrelapse deaths. One patient whose pretransplant 
DISCUSSION
This single center analysis revealed excellent survival outcomes for pediatric patients undergoing autologous transplantation for relapsed or refractory HL. Very few studies have evaluated the impact of ASCT in children/adolescents with relapsed/refractory HL, and these have reported event-free survival (EFS) between 31 and 65%. 6, [14] [15] [16] [17] Most of these events were relapses or disease progression. In these studies, pretransplant disease status was not defined by FDG-PET or gallium and remission was primarily assessed by anatomic shrinkage on CT. In contrast, response assessment by FDG-PET has been very common in the adult series. Our 5-year PFS of 95% in the negative FI group exceeded the disease-free survival reported in pretransplant PET negative adult patients, which is in the range of 55-85%. [18] [19] [20] [21] Recently, Moskowitz et al. observed a 2-year PFS of ∼92% in PET negative patients who had received brentuximab vedotin (Bv) alone or Bv followed by augmented ICE before undergoing transplant. 22 However, unlike in prior studies or our analysis, PET negativity was defined as score ≤2 in the five-point Deauville scale.
Many of the adult studies have evaluated the prognostic significance of pretransplant FDG-PET. Given the era our patients were treated, six early patients had gallium scans instead of PET. FDG-PET has largely replaced gallium as the FI of choice in the evaluation of HL.
While we do not assume FDG-PET and gallium have equal sensitivity for detecting disease, two earlier studies demonstrated that both modalities were strongly predictive for outcome in relapsed/refractory HL without any difference in outcome for patients evaluated by these modalities pretransplant. 7, 8 Hence, our decision to include the six early patients who had gallium scans seemed justified and should not undermine our results.
We recognize that our patient population may have been selected, that may in part account for our excellent outcomes. However, the patients in our cohort were not the most favorable. Multiple studies have shown remission duration <1 year, presence of extranodal disease, and B symptoms at relapse to be important prognostic factors in relapsed/refractory HL. 12, [23] [24] [25] [26] [27] Likewise, a multivariate analysis of 606 children, adolescents, and young adults with relapsed or refractory HL (median age 23 years, range 3-29 years) who underwent ASCT demonstrated similar results. 28 In our analysis, 82% of patients were in remission for less than a year and 29% had extranodal disease at the time of disease relapse. Our excellent outcomes despite having a significant percentage of high-risk patients (refractory disease and remission less than a year) may be the consequence of a high proportion of patients who were negative by FI pretransplant, after we had administered additional lines of salvage therapy to patients who were not in metabolic remission after first-line salvage. Also, the fact that most patients who had persistent PET avidity before transplant were administered posttransplant irradiation is postulated to improve survival for that group.
Pre-transplant FI was not predictive of outcome in our analysis (95 vs. 75%, P = 0.057). However, it is notable that the only secondary treatment failure observed was in a patient who was PET positive prior to transplant. There are few potential explanations for our results. Because of the small number of patients, the small proportion of patients who were pretransplant FI positive (16% in our cohort, whereas most adult studies report >30% 7, 20, 21, 29 ) and the lack of events, we may not have been sufficiently powered to demonstrate a difference in survival between the FI negative and positive groups. These same reasons also likely underlie our inability to identify any of the known prognostic factors (e.g., remission duration, extranodal disease, B symptoms at relapse) in our univariate analysis. Conversely, pretransplant FI may not be truly predictive in children and adolescents, which may reflect differences in disease biology between this age group and the adults.
Literature on the role of consolidative posttransplant RT in relapsed/refractory HL, though inconclusive, appears to suggest there might be a survival benefit. Shafer et al. observed that children irradiated after autologous transplant had a 2-year PFS of 88% (95% CI: 39-98) versus 52% (95% CI: 26-72) (P = 0.1) if RT was not administered. 11 In that series, patients were selected for IFRT if they had bulky disease or were PET positive after transplant. Similarly, Moskowitz et al. found pretransplant radiation to be marginally significant for EFS (P = 0.055). 8 More than 30% of our patients received posttransplant RT, thus it is plausible this may have boosted our survival.
The potential impact of the transplant conditioning and salvage chemotherapy regimens used also warrants consideration. Cyclophosphamide, carmustine and etoposide (CBV) and BEAM are the most common conditioning regimens used in relapsed/refractory HL. 30 Only few studies have compared these two regimens, 31, 32 but there has never been a true head-to-head controlled comparison. Williams et al.
reported lower risk of disease progression and longer survival associated with the use of BEAM versus CBV (5-year PFS of 92% vs. 73%,
. 30 Yet, this may have been confounded by benefits related to improved supportive care and patient selection, given the more recent patients in that study received BEAM.
The salvage therapies used in our analysis were predominantly standard regimens for relapsed/refractory HL. Consequently, it will be difficult to determine their impact on our outcomes. Several investigators have shown that a favorable response to first-line salvage chemotherapy (chemosensitivity) (defined by at least 50% tumor reduction on bidimensional measurement on conventional CT) strongly predicts survival in patients with relapsed or refractory HL. 10, 11, 33, 34 Metzger et al. reported that children who had chemosensitive disease had a 5-year OS of 97.2%, compared to 17.9% in the group that did not respond (P < 0.0001) 10 In that study, most of the patients who had chemo-sensitive disease were also in metabolic remission by PET. We did not include CT response in our analysis and our salvage regimens differed significantly from those of the authors, limiting comparison; but failure to achieve metabolic remission after first-line salvage therapy did not have any significant impact on our survival outcome. Furthermore, normalization of pre-ASCT FI after second-line salvage chemotherapy has been shown to result in improved survival, when compared to chemosensitive disease with persistent abnormalities on FI. 35 We observed that more than 60% of the patients who were PET positive after first-line salvage achieved metabolic remission after additional alternative noncross-resistant chemotherapy regimens. While this is encouraging, it also implies that some children will not get into metabolic remission with standard salvage chemotherapy. Although small numbers, we observed that patients with primary refractory disease were less likely to respond to additional salvage regimens, consistent with earlier observations of refractory disease being predictive of a poor response to salvage therapy. 10, 36 Patients deemed unresponsive to standard chemotherapy may be candidates for novel therapies before ASCT. The inclusion of the anti-CD30 antibody conjugate, brentuximab, and programmed death 1 inhibitors such as nivolumab and pembrolizumab have improved the success rate of salvage treatment in adult patients with relapsed/refractory HL. [37] [38] [39] Furthermore, brentuximab given as consolidation post-ASCT has been shown to improve PFS in adults with relapsed/refractory HL. 40 Two active Children's Oncology Group trials are investigating incorporation of novel therapies in relapsed/refractory pediatric HL.
AHOD1221 is evaluating the combination of brentuximab with gemcitabine (NCT01780662), while the recently approved AHOD1721 study is examining if a combination of nivolumab and brentuximab, followed by brentuximab and bendamustine (NCT02927769), is safe and effective in children, adolescents, and young adults who had failed firstline salvage therapy.
In conclusion, acknowledging the potential limitations of our retrospective design, small number of patients, and nonuniformity in modalities of FI and salvage therapies administered, our analysis reveals outstanding outcomes for children and adolescents with relapsed or refractory HL. There were very few relapses to identify the predictive value of pretransplant FI, but pediatric patients in metabolic remission either by PET or gallium pretransplant had a better survival than reported in the adult literature. Further studies are warranted to determine the true prognostic value of pretransplant FI in pediatrics.
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